News

Medtech entrepreneurs are invited to showcase their innovations at the 2025 Early-Stage Innovation Forum (ESIF), a premier platform for emerging developers to present their cutting-edge solutions at the AusMedtech 2025 conference in Sydney 6 – 8 May.

Clinical-stage biotechnology company Vaxxas has announced the publication of data supporting the potential use of its high-density microarray patch technology to deliver nucleic acid-based vaccines in collaboration with The University of Queensland and Technovalia.

Australian company Atmo Biosciences has announced the publication of pivotal clinical study data in Clinical Gastroenterology and Hepatology.

The George Institute for Global Health, a leading medical research organisation, has appointed Dr Paul Schreier as its new board chair.

"Through his leadership, BioMelbourne Network has solidified its position within the Victorian health technologies sector, delivering positive outcomes for members and stakeholders and contributing to the advancement of life sciences," said the organisation.

A new report by Telix says the tens of thousands of Australians could miss out on a new era of cancer treatment without action from the government to secure the viability of the nuclear medicine sector, including enforcing regulatory standards.

The 8th International Conference on Microneedles - Pathways to Products, taking place from 11-14 May 2025 in Brisbane, is set to be a milestone event as the first of its kind in the southern hemisphere.

Clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of Darren Keamy as its chief financial officer and company secretary starting today.

“This investment is a welcome top-up of our funding capacity to support our plans in 2025,” said Dr Peter Molloy, executive chairman of Firebrick.

Australian startup company Cortical Labs has launched CL1, the world’s first commercial biological computer, which fuses lab-cultivated neurons from human stem cells with silicon to create a new, more advanced form of artificial intelligence.

Avecho Biotechnology (ASX:AVE) and Sandoz have signed an exclusive ten-year development and licensing agreement for the commercial rights to the Australian company's phase 3 cannabidiol capsule for insomnia in Australia.

CSL Seqirus has signed an agreement Esperion Therapeutics for the exclusive license and distribution agreement to commercialise NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Australia and New Zealand.